UTHR
United Therapeutics Corp

2,410
Mkt Cap
$19.07B
Volume
434,772.00
52W High
$459.48
52W Low
$266.98
PE Ratio
16.46
UTHR Fundamentals
Price
$426.21
Prev Close
$421.64
Open
$424.16
50D MA
$393.10
Beta
0.37
Avg. Volume
1.05M
EPS (Annual)
$24.64
P/B
2.66
Rev/Employee
$2.2M
Loading...
Loading...
News
all
press releases
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7h ago
News Placeholder
More News
News Placeholder
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1d ago
News Placeholder
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zacks·1d ago
News Placeholder
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release...
Business Wire·8d ago
News Placeholder
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest...
Business Wire·10d ago
News Placeholder
Is IPF the Next Big Market Opportunity for United Therapeutics?
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
Zacks·22d ago
News Placeholder
Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals
NextEra Energy expands its renewable pipeline, U.S. Bancorp builds on earnings momentum, and Air Products eyes growth despite headwinds.
Zacks·23d ago
News Placeholder
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.
Zacks·1mo ago
News Placeholder
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1mo ago
News Placeholder
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
Zacks·2mo ago

Latest UTHR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.